{"name":"Avobis Bio, LLC","slug":"avobis-bio-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AVB-114","genericName":"AVB-114","slug":"avb-114","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"AVB-114","genericName":"AVB-114","slug":"avb-114","phase":"phase_2","mechanism":"AVB-114 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gJBVV95cUxQNFI1S3NhMWZ3ajlNNDNnMjJTQVdLSVVUOFRnOXc2eGZySUM2NTViRXkzZ2dka3BsckZuUEx3clpKcUNfNm0tcFZmRVlzSW1qOU1Vcm91TWlnM2JvVEZKQ2lkT3FEbWZCczVsYUlhVUo0eHp0OFhLQWZWUnhsd192dGM3a0dTcnFUNmlrMmJKWUlydHJiZnE2dXp3NmVYRXQzdVl0eG92Tm9fUEhENlNyOExZZ1hlN0EzM055TGgwSUlELWY0MWFrR0Q5YkF6WThLUHVhUlMzT0diWGpSdDdvRDV6YldMR0xFdUx6UlZJekF5MEctTWRUTU4tRnZ4NFJWWnQtcHRQZGlwZ2trLXdpZTF3WUJaemUzckZRZGlaM2VESUJIRVlaa0Y1Xzh0emh1ZWpWWl9LeFpkdW9Ra0pVeVFhUl9ySU11MzdQUXNsYWE0NFBaNG5FYmpn?oc=5","date":"2026-01-29","type":"trial","source":"prnewswire.com","summary":"Avobis Bio Announces Expanded Primary Analysis Results from the Randomized Multicenter STOMP2 Clinical Trial to be Presented at European Crohn's and Colitis Organisation (ECCO) Congress - prnewswire.c","headline":"Avobis Bio Announces Expanded Primary Analysis Results from the Randomized Multicenter STOMP2 Clinical Trial to be Prese","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-29","type":"trial","source":"prnewswire.com","summary":"Avobis Bio Presents Positive Primary Analysis Results from the Randomized Multicenter STOMP2 Clinical Trial at a Plenary Session of the American College of Gastroenterology's Annual Scientific Meeting","headline":"Avobis Bio Presents Positive Primary Analysis Results from the Randomized Multicenter STOMP2 Clinical Trial at a Plenary","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQVEx1cmJBTTVLN3lVeXhpN1R5OXpDUE5PWm5sRUVXRUdvRkJNd0hoeTdUczV4SUk5NEh5UHB2d2lkaDQwTWUxeTQtZkhwWDV2RkE4dXJFNjk0YzhEYTBWY3QxU2RpMGFWNmxJZ2NaTE1uOTlkZjM3eUYtS3h0bG9rZHgzd1lmTkF4a3dwVTNVcG5mLUdCYmZuWVNCRXl1TnlGNjBzU1pMbDU5UDN4cGVLU1pkN1AzU21DX1AxbWJGOGRMazE2cUEzZ1JVRll1Y1Uta2plSUMwZS1IZDc4ZnhyWHhXNGtiRXpYM2NrZXJCWHNyZw?oc=5","date":"2025-10-03","type":"regulatory","source":"prnewswire.com","summary":"FDA Grants RMAT Designation to Avobis Bio's Implantable Cell Therapy AVB-114 for Crohn's Perianal Fistulas - prnewswire.com","headline":"FDA Grants RMAT Designation to Avobis Bio's Implantable Cell Therapy AVB-114 for Crohn's Perianal Fistulas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPMGhPdGxVQ2ZhVEN3MkFUXy1rb0VSR3Y3Y3FuWXhzVWdMVmVkdkpHZnZXMWRHcnAyeEVUTVN0X09tRDA3bVdtR2M4M1lVNFo5UXNWWjEzRkNoSjBJS0llaXZNV0VSaEFqOFpvcjFoa0paYkNCZi1HdGR4OHBVY2Y4eGFTNWNLUzFkaHgydjNSRkxiNDdsU2c1WWl1elI0aUNfRmh2c0xYMENfZ0oteDk5c1hRY0swVjVkMjJaMF93eGpSaTBnVFJETjNxMFpSOUx0c1Z5N0VBdlFjYzlpNnhrcGxBbFAzZ20ycVE?oc=5","date":"2025-04-15","type":"pipeline","source":"prnewswire.com","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - prnewswire.com","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQZGRIendfeXFkVE9JcTZuS29SLW5QU2I2WFM1R29kaUpRZlRVbzRLZjZfRnFSQV9GOXNfeXgyWVlLbGtHbG1wQzA0dGVNYk15Z3FNVGV2aEtMWDNhWnRubTNpbXo1MlpnM0o5WUVjdmdHdWV0THFrb09vQl9fTnUwTjBPMFQ0WlBLT3dwdkFMNWpuLTJhRTR0ZXdqeEZjOFRzWFptMUdfeHl5MmlDYUQ4UEUwT09Yb2w4aFkxbl81WW5leHdtUXJYVXB1R0xiZ0pmMXkyMzZoUDV6NnBxOC1sXzdRNTk5ZjQ?oc=5","date":"2025-02-28","type":"regulatory","source":"BioSpace","summary":"Avobis Bio Receives FDA Fast Track Designation for AVB-114 Implantable Cell Therapy for Crohn's Perianal Fistulas - BioSpace","headline":"Avobis Bio Receives FDA Fast Track Designation for AVB-114 Implantable Cell Therapy for Crohn's Perianal Fistulas","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}